Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $0.73 in the prior trading day, Vistagen Therapeutics Inc (NASDAQ: VTGN) closed at $0.73, up 0.07%. In other words, the price has increased by $0.07 from its previous closing price. On the day, 2.68 million shares were traded. VTGN stock price reached its highest trading level at $0.747 during the session, while it also had its lowest trading level at $0.682.
Ratios:
Our goal is to gain a better understanding of VTGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 5.79. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTGN now has a Market Capitalization of 28768486 and an Enterprise Value of -46541512. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.10 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at -64.551 whereas that against EBITDA is 0.713.
Stock Price History:
The Beta on a monthly basis for VTGN is 0.20, which has changed by -0.7402135 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, VTGN has reached a high of $5.14, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is -80.46%, while the 200-Day Moving Average is calculated to be -75.58%.
Shares Statistics:
The stock has traded on average 2.24M shares per day over the past 3-months and 10864440 shares per day over the last 10 days, according to various share statistics. A total of 38.89M shares are outstanding, with a floating share count of 33.66M. Insiders hold about 14.78% of the company’s shares, while institutions hold 44.98% stake in the company. Shares short for VTGN as of 1765756800 were 1791894 with a Short Ratio of 0.80, compared to 1763078400 on 1517368. Therefore, it implies a Short% of Shares Outstanding of 1791894 and a Short% of Float of 6.4799999999999995.
Earnings Estimates
. The current assessment of Vistagen Therapeutics Inc (VTGN) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.2 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.73 and -$1.99 for the fiscal current year, implying an average EPS of -$1.83. EPS for the following year is -$1.23, with 4.0 analysts recommending between -$0.8 and -$1.69.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for VTGN’s current fiscal year. The highest revenue estimate was $1.4M, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $884k. In the same quarter a year ago, actual revenue was $486k
